Walder Wyss advised Eurazeo Infrastructure Partners (EIP) on the Swiss law aspects of an investment in battery storage developer Terralayr. Pursuant to the transaction, EIP will provide — together with the existing investors — growth capital to
Search Results for: Walder wyss
Walder Wyss advised Swiss medtech company SIS Medical in connection with an investment by Claret Capital Partners — a growth debt fund manager with a focus in technology, life sciences and climate tech companies across Europe.
Freiburg-based bicycle leasing specialist JobRad Group completed the acquisition of MyBikePlan, a Swiss Swiss e-commerce and mobility startup focused on e-bikes. In connection with the deal, Walder Wyss advised JobRad Group, while CMS Switzerland represented
Walder Wyss advised Swiss Life as the Swiss insurance company placed a CHF 225 million dated subordinated bond, first callable in January 2032. The bonds in question were placed with investors in the Swiss Franc market. The
Walder Wyss advised Linamar Corporation, as the Canadian company acquired the iron foundry of Georg Fischer in Leipzig. The transaction amounts to € 45 million. Headquartered in Guelph (Ontario), Linamar is a globally active manufacturing company, employing
Walder Wyss advised Crédit Mutuel Equity (CME), as the company was appointed — together with IDIA Capital Investissement — by Polenghi, to lead a new investment round, following the exit of Progressio SGR. Headquartered in Italy,
Walder Wyss advised TECregen, as the Basel-based biotechnology company raised CHF 10 million in a seed financing round. The investor base Boehringer Ingelheim Venture Fund (BIVF) led the round in question, with participation from LifeSpan
Welcome to Signed, Sealed, Weekend, our weekly newsletter recap. Check out the news of the week: · SIX-listed Santhera Pharmaceuticals has signed an exclusive licensing agreement with biopharma company Nxera Pharma for the development, manufacturing and
Walder Wyss officialised the promotion of Iliana Djagova (pictured right) to partner in the corporate and M&A team, and Matthias Lötscher (pictured left) to counsel in the banking & finance team, both
Walder Wyss advised Allegria Therapeutics, a Basel-based biotech company developing therapies for mast cell-mediated diseases, throughout its USD 5.1 million seed extension funding round. The context ALK Abelló led the round in question, with support from
